Third Party Agreements - Additional Information (Details) - USD ($) $ in Millions		9 Months Ended
	Jan. 28, 2022	Sep. 30, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research and development in process 1		$ 1.0
License agreement termination description		twelve (12) years
Regeneron Pharmaceuticals, Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized		$ 5.0
Exercise Fee Paid	$ 20.0	20.0
Licence agreement additional revenue recognised		25.0
Non refundable upfront payment received		25.0
Additional payment for research funding received		20.0
Regeneron Pharmaceuticals, Inc. | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Licence agreement additional amount payable of option exercise fees		$ 80.0